News | June 23, 2022
Glenmark Pharmaceuticals to address USFDA’s observation
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
A total of five observations for Goa and 17 for Monroe
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
